GlassScriptPhysician profile
Paul Robert Hughes
NPI 1962943209
$1,637.99
in general payments reported to CMS, 2019-2025
21 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.88 · 2022: $349 · 2023: $156 · 2024: $474 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $223.17 | 2024-2025 | Darzalex, Rybrevant, Tecvayli |
| Novartis Pharmaceuticals Corporation | $199.04 | 2022-2025 | |
| Abbvie INC. | $134.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.51 | 2024-2025 | Calquence |
| Genzyme Corporation | $106.85 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $106.51 | 2024-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $100.84 | 2022-2023 | Imbruvica, Epkinly |
| Amgen INC. | $85.71 | 2021-2022 | |
| Pfizer INC. | $83.19 | 2024-2025 | |
| Genentech, INC. | $82.02 | 2023 | Venclexta, Lunsumio |
| Glaxosmithkline, LLC. | $72.71 | 2021-2025 | Ojjaara |
| Pharmacosmos Therapeutics INC. | $72.13 | 2022-2024 | Monoferric |
| Genentech USA, INC. | $68.06 | 2022-2023 | Venclexta |
| Syndax Pharmaceuticals, INC. | $34.90 | 2025 | |
| Alnylam Pharmaceuticals INC. | $34.25 | 2025 | Amvuttra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $21.79 | 2025 | Orbactiv, Rezzayo |
| Adc Therapeutics America, INC. | $21.75 | 2025 | |
| Octapharma USA, INC. | $20.45 | 2024 | Octagam Immune Globulin (Human) |
| Janssen Scientific Affairs, LLC | $15.37 | 2024 | Imbruvica, Darzalex, Talvey |
| La Jolla Pharmaceutical Company | $14.82 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.70 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.